Viracta Therapeutics Valuation
| VIRX Stock | USD 0.15 0.01 7.14% |
Viracta Therapeutics seems to be undervalued based on Macroaxis valuation methodology. Our model measures the value of Viracta Therapeutics from inspecting the company fundamentals such as Shares Outstanding of 39.74 M, shares owned by institutions of 50.00 %, and Return On Equity of -2.09 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Viracta Therapeutics' valuation include:
Price Book 3.0028 | Enterprise Value 1.7 M | Enterprise Value Ebitda (0.48) |
Undervalued
Today
Please note that Viracta Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Viracta Therapeutics is based on 3 months time horizon. Increasing Viracta Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Viracta Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Viracta Stock. However, Viracta Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.15 | Real 2.3 | Target 8.75 | Hype 0.15 |
The intrinsic value of Viracta Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Viracta Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Viracta Therapeutics helps investors to forecast how Viracta stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Viracta Therapeutics more accurately as focusing exclusively on Viracta Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Viracta Therapeutics' intrinsic value based on its ongoing forecasts of Viracta Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Viracta Therapeutics' closest peers.
Viracta Therapeutics Cash |
|
Viracta Valuation Trend
Analysing the historical paterns of Viracta Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Viracta Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Viracta Therapeutics Total Value Analysis
Viracta Therapeutics is at this time projected to have valuation of 1.66 M with market capitalization of 5.88 M, debt of 25.56 M, and cash on hands of 83.14 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Viracta Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.66 M | 5.88 M | 25.56 M | 83.14 M |
Viracta Therapeutics Asset Utilization
One of the ways to look at asset utilization of Viracta is to check how much profit was generated for every dollar of assets it reports. Viracta Therapeutics has a negative utilization of assets of -0.57 %, losing $0.00572 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Viracta Therapeutics shows how discouraging it operates for each dollar spent on its assets.Viracta Therapeutics Ownership Allocation
Viracta Therapeutics shows a total of 39.74 Million outstanding shares. 30% of Viracta Therapeutics outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Viracta Therapeutics Profitability Analysis
Net Loss for the year was (51.06 M) with profit before overhead, payroll, taxes, and interest of 0.About Viracta Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Viracta Therapeutics. We calculate exposure to Viracta Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Viracta Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -492 K | -467.4 K | |
| Pretax Profit Margin | (182.25) | (173.13) | |
| Operating Profit Margin | (180.31) | (171.29) | |
| Net Loss | (183.99) | (174.79) | |
| Gross Profit Margin | 0.84 | 0.80 |
Viracta Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 38.6 M |
Viracta Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Viracta Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Viracta we look at many different elements of the entity such as Viracta's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Viracta Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Viracta Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Viracta Therapeutics' worth.Additional Tools for Viracta Stock Analysis
When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.